Pre-Markets in Red but Improving on New Data

Pre-market activity saw mixed signals with major indices slightly down, while the July Durable Goods report showed improvement, declining -2.8% but exceeding consensus and rebounding +1.1% ex-transportation, suggesting some economic resilience. However, June Case-Shiller Home Prices cooled to +2.1%, the lowest since July 2023, with housing wealth growth lagging inflation. Corporate news provided positive catalysts, as Eli Lilly shares gained +2.5% on promising Phase-3 results for its weight loss pill, and Canadian banks BMO and BNS saw shares rise after beating earnings expectations.

Analysis

The pre-market session is characterized by conflicting economic signals and company-specific catalysts. On the macroeconomic front, the July Durable Goods report, while negative at -2.8%, significantly beat consensus estimates and improved from the prior month's -9.4% trough, which was the lowest reading since April 2020. More importantly, when stripping out volatile transportation orders, a core strength emerges with a +1.1% gain, the highest since last September, and shipments posting their strongest performance of 2025 at +0.7%. This suggests underlying industrial resilience despite headwinds from a new tariff policy. In stark contrast, the housing market shows clear signs of deceleration. The June Case-Shiller Home Price Index posted its slowest growth in nearly two years at +2.1%, and crucially, the +1.9% year-over-year gain in housing wealth now lags the +2.7% inflation rate, indicating a real-term erosion of value. There is also a pronounced regional divergence, with markets like New York gaining +7.0% while Tampa and San Francisco declined -2.4% and -2.0% respectively. In corporate news, Eli Lilly (LLY) shares rose +2.5% on promising phase-3 results for a new weight loss pill, though the stock remains down year-to-date. The financial sector saw positive results from Canadian banks, with Bank of Montreal (BMO) and Bank of Nova Scotia (BNS) beating earnings expectations by 9.9% and 7.0%, respectively, leading to modest share price increases.

Key Decisions for Investors

• Given the divergence between resilient industrial data and a cooling housing market, investors should monitor upcoming consumer confidence figures to assess the net impact on the economy; the relative strength in the Russell 2000 suggests a potential tactical opportunity in small-caps.
• For Eli Lilly (LLY), the positive phase-3 trial news is a significant de-risking event, but the stock's year-to-date underperformance and the reported 10.6% patient dropout rate at the highest dosage warrant consideration before building a new position.
• The ongoing slowdown in housing, with price growth now trailing inflation, is a key risk factor that could weigh on consumer wealth and spending, necessitating a cautious approach toward sectors reliant on housing strength and a re-evaluation of real estate exposure on a regional basis due to sharp performance disparities.